olaparib,bevacizumab
roche,astrazeneca,merck
['gyn', 'ovarian', 'paola-1']
paola-1 presented at oral gyneacological session of 2022.
5-years overall survival was prolongated for half of the patients with ovarian cancer. one of the major step forward since 25 years ! #oncology #cancer #research #clinicaltrials #esmo 
Arcagy-Gineco : a non-profit independant research group at the heart of gynecologic cancer research and information